FDA Adding Managers, With Goal Of Quicker Inspection Reports
This article was originally published in The Pink Sheet Daily
Executive Summary
'Delayering' the Office of Regulatory Affairs actually means increasing the number of supervisors, FDA is realizing.
You may also be interested in...
FDA's Pazdur To Retain Drug Approval Duties In Oncology Center Of Excellence
Center for Drug Evaluation and Research's long-time director of oncology/hematology products office will continue as signatory on drug reviews even after new Cancer Moonshot-driven structure takes effect.
CDER, CBER Not Seeing Hiring Slowdown Despite US FDA Warnings
FDA officials have said hiring could be slowed if an inflationary pay increase is not included in the agency budget, but CDER and CBER continue to add staff at a steady pace.
Parallel Scientific Advice: Is The EMA User Fee Impacting Interest?
EMA charges participants to receive scientific advice through the fledgling program, unlike the US FDA, which may not fit the budgets of some complex generic sponsors. At the same time, sponsors also may simply not be aware the program exists yet.